Cannabis & THC Commercialization
Compliant formulation, manufacturing, and market strategy for regulated cannabinoid commercialization.
15+ years of controlled-substance expertise. Built for Schedule III scale.
The Schedule III Opportunity
The reclassification of cannabis to Schedule III marks a structural shift in how regulated cannabinoids will be commercialized in the United States. While many view this as a signal to move fast, we advise clients to move correctly — and we are already positioned to do so at scale.
Schedule III does not remove FDA oversight. It creates pathways for companies that already understand controlled ingredient handling, formulation discipline, documentation and traceability, and future IND and FDA drug positioning.
We are not exploring this market — we are built for it.
Why the Window Is Short
Regulatory transitions do not last. Companies that establish compliant formulations, manufacturing relationships, and market presence before guidance hardens will dominate the next phase.
We are executing during this window — not waiting for it to close.
Operational Readiness
Controlled-substance formulation expertise with in-house chemists specializing in botanical extracts, cannabinoid delivery systems, and bioavailability optimization.
Fully cGMP-certified manufacturing partner with controlled ingredient handling, documentation, and traceability for Schedule III compliance.
Non-THC nationwide wellness products + state-legal THC formulations. Structurally separated operations protecting compliance posture while capturing market margins.
From concept to compliant production without rebuilding infrastructure. Locked manufacturing, owned formulations, and baked-in compliance enable faster iteration.
Built for current enforcement reality and future FDA optionality. Positioned for IND pathways and federal drug positioning as regulations evolve.
15+ years managing regulated cannabinoid operations. Experience with formulation discipline, traceability, and compliance architecture.
Scale-First Commercial Framework
We deploy a dual-lane strategy engineered for immediate revenue and long-term federal optionality.
Lane 1: Nationwide Wellness
FDA-compliant non-THC formulations produced under full cGMP controls.
- National distribution
- DTC, retail, practitioner channels
- Clean audit trails
- Fast, defensible scale
Lane 2: State-Legal THC
Low-dose THC formulations distributed through licensed dispensaries.
- Cannabis market margins
- Formulation data collection
- Consumer behavior insights
- Structurally separated operations
Both lanes are engineered to scale independently without contaminating compliance posture.
Why We Move Faster
Most companies face bottlenecks. We eliminated them.
- Manufacturing locked with compliant partner
- Chemistry and formulation in-house
- Compliance baked into architecture
- Fast iteration cycles
- Lane 1: Nationwide FDA-compliant wellness (non-THC)
- Lane 2: State-legal THC products (licensed dispensaries)
- Independent scaling without cross-contamination
- Defensible market positioning
- Established before guidance hardens
- Market presence and formulation data
- Consumer behavior insights
- Prepared for regulatory tightening
Our Philosophy
"Speed without compliance is risk. Compliance with speed is leverage."
We are built for leverage. That's why we're already operational, already staffed, and ready to scale immediately.
Who We're Engaging With
✓ Founders seeking compliant THC-adjacent expansion
✓ Capital partners prioritizing durability over hype
✓ Licensed operators needing formulation & scale support
✓ Strategic investors focused on post-Schedule-III infrastructure